Analysts Offer Insights on Healthcare Companies: BioMarin (BMRN), Alnylam Pharma (ALNY) and Emergent Biosolutions (EBS)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin (BMRN), Alnylam Pharma (ALNY) and Emergent Biosolutions (EBS).

BioMarin (BMRN)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on BioMarin today and set a price target of $150. The company’s shares opened today at $90.19.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.5% and a 41.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on BioMarin is a Moderate Buy with an average price target of $124.50, representing a 38.0% upside. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $126 price target.

.

See today’s analyst top recommended stocks >>

Alnylam Pharma (ALNY)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Alnylam Pharma, with a price target of $147. The company’s shares opened today at $81.78.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.7% and a 42.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $133.55.

Emergent Biosolutions (EBS)

In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Emergent Biosolutions, with a price target of $64. The company’s shares opened today at $61.55.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 4.4% and a 41.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Corvus Pharmaceuticals Inc, and Stemline Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $71.80 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts